MEA Neurostimulation Devices Market

MEA Neurostimulation Devices Market Size (2023 to 2028)

The size of the Middle East and Africa neurostimulation devices market is estimated to be growing at a healthy CAGR during the forecast period.

The growing prevalence of neurological diseases in the countries of the Middle East and Africa majorly drives the growth of the MEA neurostimulation devices market. Neurological disorders such as epilepsy, headache disorders, peripheral neuropathy and Parkinson's disease are among the prevalent conditions that require the use of neurostimulation devices for effective treatment. These devices encompass implantable medical devices designed to stimulate specific areas of the brain, spinal cord and nervous system, providing therapeutic benefits to patients.

In Saudi Arabia, the impact of neurological diseases is particularly notable, with Alzheimer's disease affecting approximately 50,000 patients. Alzheimer's disease is a prominent neurodegenerative disorder that significantly impairs brain function among the affected population. The rising demand for neurostimulation devices in the MEA region is fueled by the need for advanced solutions to address neurological conditions and improve patients' quality of life. Manufacturers and healthcare providers are focusing on developing innovative devices and therapies to meet this growing demand and provide effective treatment options.

The rising demand for minimally invasive surgeries in MEA further boosts the growth of the MEA neurostimulation devices market. In recent years, there has been a significant preference among individuals for procedures that involve smaller incisions, shorter hospital stays, reduced post-operative pain and quicker recovery times compared to traditional surgeries. Minimally invasive surgeries offer numerous benefits to patients and have become a preferred choice for many seeking medical interventions.

The growing number of advancements in device manufacturing promotes the growth of the neurostimulation devices market in MEA. As the adoption of neurostimulation devices grows, manufacturers are focused on developing devices that incorporate advanced technologies like sensors and artificial intelligence. These innovations enhance the capabilities and functionalities of neurostimulation devices, catering to the evolving needs of healthcare providers and patients.

The high cost associated with neurostimulation devices primarily hampers the growth of the MEA market. The side effects of using neurostimulation devices such as allergic reactions, redness and itching hinder the market growth. Poor awareness among healthcare professionals and patients regarding the benefits and applications of neurostimulation devices in MEA inhibits the growth rate of the MEA market. The limited availability of neurostimulation devices and the associated challenges in obtaining necessary product approvals further impede the MEA market expansion.

This research report on the Middle East & Africa neurostimulation devices market is segmented and sub-segmented into the following categories.

By Technology:

• Internal
• External

By Application:

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Emerging markets such as Saudi Arabia, South Africa, and Turkey have become attractive for companies engaged in developing and commercialization of neurostimulation devices. The increase in neurological disorders and government initiatives to increase awareness through education campaigns are the main factors driving the demand for internal neuromodulation technologies in these emerging markets.

In African regions, the market for neurostimulation devices is expected to flourish. Neurostimulators are widely used to treat acute and chronic pain by delivering electrical stimuli to the brain, spinal cord, and other organs. In South Africa, there is an urgent need for significant funding to cope with the growing number of patients who have Alzheimer's disease. The number is expected to increase to 251,000 by 2032. This is expected to hamper the market growth in the country.

With investors seeking new markets in African regions, growth is expected in the years to come.

KEY MARKET PLAYERS:

Abbott, Bayer AG, Boston Scientific Corporation, IntraPace, Inc., Laborie, Inc., LivaNova PLC, Medtronic, Neuronetics, Inc., NuroPace Inc., Nevro Corp., and SPR Therapeutics are a few of the notable companies operating in the MEA neurostimulation devices market.